MedTrace Logo

Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir Combination

NCT03490097 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2018-09-20

No results posted yet for this study

Summary

The purpose of the study is to determine if statin can affect the clinical outcome of chronic hepatitis C patients receiving Sofosbuvir/Daclatasvir/Ribavirin combination

Conditions

  • Chronic Hepatitis c
  • Metabolic Syndrome

Interventions

DRUG

Simvastatin 10mg

tablets

DRUG

sofosbuvir plus daclatasvir

sofosbuvir 400mg daclatasvir 60 mg daily for 12 weeks.

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Nagwa Ali Sabri, Professor · Professor of clinical pharmacy , ASU

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-01
Primary Completion
2018-05-23
Completion
2018-05-23

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03490097 on ClinicalTrials.gov